Table 2.

Patient disposition (by investigator assessment) (N = 321)

	No. (%)
Ongoing treatment	124 (39)
Discontinued treatment	197 (61)
Disease progression	88 (27)
Adverse events	61 (19)
Drug related	50 (16)*
Non-drug related	11 (3)
Abnormal test results	4 (1)
Abnormal laboratory values	2 (< 1)
Other†	39 (12)
Death	3 (< 1)

^*Drug-related adverse events causing discontinuation included myelosuppression (n = 20; 6%), elevations of lipase or pancreatitis (n = 2; < 1%), elevations of liver enzymes or bilirubin (n = 3; < 1%), skin disorders (n = 5; 2%), diarrhea (n = 1; < 1%).

^†Other includes protocol violation, withdrawn consent, lost to follow-up, not stated, and administrative problems.